

Biocept

Completing the Answer™

Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform

February 5, 2018

Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

SAN DIEGO, Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of patents in Europe, Japan and Hong Kong for its core Target Selector™ liquid biopsy technology. In Japan, Biocept's patent no. 6234817 is entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION, and in Europe, Biocept's patent no. 2995953 is entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. In Hong Kong, Biocept's patent no. HK1191043 is entitled CELL SEPARATION USING MICROCHANNEL HAVING PATTERNED POSTS. All of these patents are directed to the capture and analysis of rare cells of interest, such as cancer cells, that are shed into the blood from solid tumors. Biocept now has 25 issued patents globally for its liquid biopsy technology platforms.



"The granting of these patents further expands Biocept's intellectual property rights regarding the use of antibody 'cocktails' and separately microfluidic devices to capture and interrogate rare cells of interest from any sample type," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "Expansion of our patent rights worldwide further establishes Biocept's proprietary position in the liquid biopsy segment."

Michael Nall, Biocept's President and CEO, added, "Expanding Biocept's patent protection around the world is an important component of our strategy and these newly issued patents strengthen the opportunity to develop business in major markets outside the U.S. We now have 25 issued patents for our core technologies and we intend to continue to broaden and leverage our intellectual property position throughout the year."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platforms capture and analyze tumor-associated molecular markers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, our ability to broaden and leverage our intellectual property in the future, the perceived benefits of our proprietary liquid biopsy technology, and our ability to develop business outside the U.S., such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov.

View original content with multimedia: <http://www.prnewswire.com/news-releases/biocept-receives-additional-patent-issuances-in-three-major-international-territories-for-its-target-selector-platform-300592847.html>

SOURCE Biocept, Inc.

Investor Contact, LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100 or Media Contact, Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109